NTLA has been the topic of several other research reports. Evercore ISI assumed coverage on Intellia Therapeutics in a report on Thursday, April 11th. They issued an outperform rating on the stock. Chardan Capital restated a buy rating and set a $57.50 price target on shares of Intellia Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research downgraded Intellia Therapeutics from a buy rating to a hold rating in a report on Tuesday, January 29th. Finally, BTIG Research initiated coverage on Intellia Therapeutics in a report on Thursday, February 7th. They set a buy rating and a $20.00 price target on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $29.08.
NTLA opened at $16.15 on Tuesday. The stock has a market capitalization of $730.38 million, a PE ratio of -8.16 and a beta of 2.95. Intellia Therapeutics has a 12 month low of $11.03 and a 12 month high of $32.95.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, February 27th. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The firm had revenue of $7.90 million for the quarter, compared to the consensus estimate of $9.92 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. The company’s quarterly revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.61) earnings per share. As a group, research analysts expect that Intellia Therapeutics will post -2.47 EPS for the current year.
In other Intellia Therapeutics news, EVP Andrew Schiermeier purchased 7,500 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $15.72 per share, for a total transaction of $117,900.00. Following the acquisition, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. We Are One Seven LLC purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $28,000. Patriot Financial Group Insurance Agency LLC boosted its position in Intellia Therapeutics by 35.8% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after acquiring an additional 1,450 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its position in Intellia Therapeutics by 20.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after acquiring an additional 995 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Intellia Therapeutics by 52.7% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 8,381 shares of the company’s stock valued at $110,000 after acquiring an additional 2,892 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Intellia Therapeutics during the 4th quarter valued at approximately $112,000. Institutional investors own 69.64% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Recommended Story: Technical Analysis
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.